Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Blood Pressure
← New Search

Blood Pressure

Educational clinical summary of Blood Pressure for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is intended for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Clinical judgment must always supersede textbook knowledge.

Blood Pressure

Overview

  • Definition: Blood pressure (BP) is the force exerted by circulating blood against the walls of the body's arteries, the major blood vessels. It is typically expressed as two numbers: systolic pressure (the higher number, representing pressure when the heart beats and pumps blood) and diastolic pressure (the lower number, representing pressure when the heart rests between beats).
    • Hypertension (High Blood Pressure): A chronic medical condition characterized by persistently elevated arterial blood pressure. It is often asymptomatic and is a major risk factor for cardiovascular disease.
  • Epidemiology:
    • Prevalence: Hypertension is a global health crisis, affecting an estimated 1.28 billion adults aged 30-79 years worldwide (WHO, 2021).
    • Demographics:
      • Prevalence increases with age; over 60% of individuals aged 60 and older have hypertension.
      • More common in men at younger ages, but women's prevalence increases after menopause, often surpassing men's.
      • Significant racial/ethnic disparities exist, with a higher prevalence and severity observed in non-Hispanic Black adults in the U.S.
      • Approximately 1 in 3 American adults have hypertension.
  • Classification:
    • ACC/AHA 2017 Guidelines for Adults:
      • Normal: Systolic <120 mmHg AND Diastolic <80 mmHg
      • Elevated: Systolic 120-129 mmHg AND Diastolic <80 mmHg
      • Hypertension Stage 1: Systolic 130-139 mmHg OR Diastolic 80-89 mmHg
      • Hypertension Stage 2: Systolic ≥140 mmHg OR Diastolic ≥90 mmHg
      • Hypertensive Crisis: Systolic >180 mmHg AND/OR Diastolic >120 mmHg (further classified as urgency or emergency based on presence of target organ damage).
    • Note: Diagnosis of hypertension typically requires two or more readings on two or more separate occasions, measured properly.

Pathophysiology

  • Mechanism: Blood pressure is determined by cardiac output (CO) multiplied by total peripheral resistance (TPR) (BP = CO x TPR). The regulation of BP involves complex interactions between multiple systems:
    1. Renin-Angiotensin-Aldosterone System (RAAS): Renin, secreted by the kidneys in response to low BP, leads to the formation of Angiotensin II, a potent vasoconstrictor that also stimulates aldosterone release (leading to sodium and water retention), thereby increasing BP.
    2. Sympathetic Nervous System (SNS): Norepinephrine and epinephrine released from nerve endings and adrenal medulla increase heart rate, cardiac contractility, and peripheral vasoconstriction.
    3. Endothelial Dysfunction: Impaired production of vasodilators (e.g., nitric oxide) and increased production of vasoconstrictors (e.g., endothelin-1) by the endothelium contribute to increased vascular resistance.
    4. Vascular Remodeling: Chronic hypertension leads to structural changes in arterial walls (e.g., hypertrophy, fibrosis), increasing stiffness and resistance.
    5. Renal Mechanisms: Kidneys play a critical role in long-term BP regulation by controlling extracellular fluid volume through sodium and water excretion.
    6. Genetic Factors: Polygenic inheritance plays a significant role in essential hypertension. - Primary (Essential) Hypertension: Accounts for 90-95% of cases; multifactorial etiology with no identifiable secondary cause. - Secondary Hypertension: Accounts for 5-10% of cases; caused by an underlying identifiable and often reversible condition (e.g., renal parenchymal disease, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, thyroid disease, obstructive sleep apnea, coarctation of the aorta).
  • Risk Factors:
    • Non-Modifiable:
      • Age (risk increases with age)
      • Genetics/Family History (first-degree relative with HTN)
      • Race/Ethnicity (higher prevalence in African Americans)
      • Sex (earlier onset in men, higher prevalence in women post-menopause)
    • Modifiable:
      • Unhealthy diet (high sodium, low potassium, high saturated/trans fats)
      • Physical inactivity
      • Obesity/Overweight (BMI ≥25 kg/m²)
      • Excessive alcohol consumption (>2 standard drinks/day for men, >1 for women)
      • Tobacco use (smoking, vaping)
      • Dyslipidemia (high LDL, low HDL, high triglycerides)
      • Diabetes mellitus (type 1 or 2)
      • Psychological stress
      • Certain medications (e.g., NSAIDs, oral contraceptives, decongestants, corticosteroids, some antidepressants).
  • Protective Factors:
    • DASH (Dietary Approaches to Stop Hypertension) diet: rich in fruits, vegetables, whole grains, lean protein, low-fat dairy; low in saturated/trans fats, cholesterol, added sugars, and sodium.
    • Regular aerobic physical activity (e.g., 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity per week).
    • Maintaining a healthy weight (BMI 18.5-24.9 kg/m²).
    • Limiting sodium intake (<2300 mg/day, ideally <1500 mg/day for most adults).
    • Moderate alcohol consumption.
    • Smoking cessation.
    • Stress management techniques.

Clinical Presentation

Signs and Symptoms

  • Cardinal Features: Hypertension is notoriously called the "silent killer" because it is often asymptomatic until severe or target organ damage occurs.
  • Early Signs: Typically none. Non-specific symptoms like headache, dizziness, or fatigue are rarely directly caused by uncomplicated hypertension unless severe (e.g., BP >180/120 mmHg).
  • Advanced Signs: Symptoms arise from target organ damage or secondary causes:
    • Cardiovascular: Chest pain (angina, MI), dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema (heart failure).
    • Neurological: Headache (especially occipital, morning, throbbing with severe HTN), dizziness, blurred vision, transient ischemic attack (TIA), stroke (weakness, numbness, speech changes), confusion, seizures (hypertensive encephalopathy).
    • Renal: Polyuria, nocturia, hematuria, peripheral edema (renal failure).
    • Ophthalmological: Blurred vision, vision loss, scotomas (retinopathy).
    • Peripheral Vascular: Leg pain with exertion (claudication).
    • Other: Epistaxis (nosebleeds), flushing, palpitations, sweating (pheochromocytoma), muscle weakness, polyuria (primary aldosteronism).
  • Atypical Presentations:
    • White-coat hypertension: Elevated clinic BP readings but normal out-of-office readings (HBPM or ABPM).
    • Masked hypertension: Normal clinic BP but elevated out-of-office readings.
    • Isolated systolic hypertension: Common in the elderly, where systolic BP is elevated but diastolic BP is normal.

Physical Examination

  • Inspection:
    • General appearance: signs of distress (in crisis), obesity, Cushingoid features (secondary HTN).
    • Fundoscopy: Hypertensive retinopathy (arteriolar narrowing, AV nicking, hemorrhages, exudates, papilledema in severe cases).
    • Peripheral edema: Suggests heart failure or kidney disease.
  • Palpation:
    • Radial-femoral delay: Suggests coarctation of the aorta (especially in younger patients).
    • Pulses: Diminished or absent peripheral pulses (peripheral artery disease).
    • Thyroid gland: Enlargement (hyperthyroidism).
    • Abdomen: Renal bruits (renal artery stenosis), palpable kidneys (polycystic kidney disease).
  • Special Tests:
    • Accurate Blood Pressure Measurement (Crucial):
      • Patient seated quietly for 5 minutes, arm supported at heart level, feet flat on floor, no talking.
      • Appropriate cuff size (bladder encircles 80% of arm circumference, width covers 40%).
      • Measure BP in both arms initially; use arm with higher reading for subsequent measurements.
      • Average two or more readings obtained on at least two separate occasions.
    • Orthostatic Blood Pressure: Measure BP after 5 minutes supine, then 1 and 3 minutes after standing. A drop in SBP ≥20 mmHg or DBP ≥10 mmHg indicates orthostatic hypotension.
    • Ankle-Brachial Index (ABI): Ratio of ankle to brachial BP; helps assess peripheral artery disease.

Diagnostic Approach

History Taking

  • Key Questions:
    • Duration and highest recorded BP: Provides context for severity and urgency.
    • Symptoms of end-organ damage: Chest pain, dyspnea, neurological symptoms, visual changes, claudication.
    • Symptoms suggestive of secondary hypertension:
      • Sudden onset or rapid worsening of HTN.
      • HTN refractory to multiple agents.
      • Age of onset (<30 or >65 without typical risk factors).
      • Episodic headaches, palpitations, sweating (pheochromocytoma).
      • Muscle weakness, polyuria, polydipsia (primary aldosteronism).
      • Snoring, daytime sleepiness, witnessed apneic episodes (obstructive sleep apnea).
      • Heat/cold intolerance, weight changes (thyroid disease).
    • Medication review: Current prescription, OTC, supplements, herbal remedies, illicit drugs (e.g., cocaine, amphetamines).
    • Family history: HTN, heart disease, stroke, diabetes, kidney disease.
    • Lifestyle: Dietary habits (sodium intake), physical activity, smoking, alcohol use, stress levels.
    • Home Blood Pressure Monitoring (HBPM) records: Essential for diagnosis confirmation and white-coat/masked HTN.
  • Red Flags:
    • Acute severe headache, visual disturbances, altered mental status, chest pain, acute dyspnea, sudden onset neurological deficits: Suggests hypertensive emergency requiring immediate attention.
    • New onset HTN in children or young adults, or sudden onset/refractory HTN in older adults: High suspicion for secondary causes.

Laboratory Tests

  • First-Line (Routine Evaluation): To assess overall health, identify comorbidities, and screen for target organ damage or common secondary causes.
    • Complete Metabolic Panel (CMP): Electrolytes (Na, K, Cl, HCO3), Blood Urea Nitrogen (BUN), Creatinine, Estimated Glomerular Filtration Rate (eGFR) – to assess renal function and baseline electrolytes.
    • Fasting Glucose (or HbA1c): To screen for diabetes.
    • Lipid Panel (Fasting): Total cholesterol, HDL, LDL, triglycerides – to assess dyslipidemia.
    • Complete Blood Count (CBC).
    • Thyroid-Stimulating Hormone (TSH): To screen for thyroid dysfunction.
    • Urinalysis: To screen for proteinuria, hematuria, or signs of kidney disease.
    • Electrocardiogram (ECG): To assess for left ventricular hypertrophy (LVH) or other cardiac abnormalities.
  • Confirmatory (for diagnosis):
    • Ambulatory Blood Pressure Monitoring (ABPM): Gold standard for confirming hypertension, diagnosing white-coat or masked HTN, and assessing nocturnal dipping. Requires wearing a cuff for 24 hours.
    • Home Blood Pressure Monitoring (HBPM): Recommended for all patients with suspected or diagnosed hypertension. Provides multiple readings over time in a familiar environment. Patients should measure BP twice daily for 7 days, discarding the first day's readings, and averaging the rest.
  • Monitoring: Regular re-evaluation of first-line tests, especially electrolytes and renal function for patients on diuretics, ACE inhibitors, or ARBs.
  • Specific Tests for Secondary Hypertension (if clinically indicated):
    • Primary Aldosteronism: Aldosterone-to-renin ratio (ARR). If elevated, confirm with salt loading test.
    • Pheochromocytoma: Plasma-free metanephrines or 24-hour urine fractionated metanephrines and catecholamines.
    • Renal Artery Stenosis: Renal artery duplex ultrasound, CT angiography (CTA), or MR angiography (MRA).
    • Cushing's Syndrome: 24-hour urine free cortisol, overnight dexamethasone suppression test.
    • Coarctation of Aorta: Echocardiogram.

Imaging

  • Recommended (Routine):
    • Electrocardiogram (ECG): To identify Left Ventricular Hypertrophy (LVH), a common sign of target organ damage.
  • Advanced (Based on clinical suspicion):
    • Echocardiogram: To assess cardiac structure and function, quantify LVH, ejection fraction, and valvular disease. Essential if LVH suspected on ECG or symptoms of heart failure.
    • Renal Artery Duplex Ultrasound: Initial screening for renal artery stenosis, especially in patients with resistant HTN or sudden onset of HTN/kidney injury.
    • CT Angiography (CTA) or MR Angiography (MRA) of Renal Arteries: More definitive imaging for renal artery stenosis.
    • Adrenal CT/MRI: If pheochromocytoma or primary aldosteronism is suspected and biochemical tests are positive.
    • Brain CT/MRI: For evaluation of neurological symptoms, stroke, or hypertensive encephalopathy.
    • Chest X-ray: Not routinely recommended for HTN evaluation, but can show cardiomegaly or pulmonary congestion in cases of heart failure.

Management

Acute Management (Hypertensive Crisis)

  • Hypertensive Crisis: SBP >180 mmHg and/or DBP >120 mmHg.
    • Hypertensive Urgency: Severe BP elevation WITHOUT acute or progressing target organ damage.
      • Immediate: Do not rapidly lower BP to normal levels, as this can lead to hypoperfusion. Oral antihypertensive agents are preferred.
      • Stabilization: Reduce BP gradually over 24-48 hours. Aim for BP <160/100 mmHg.
      • Emergency: Not an emergency. Patients can typically be managed in an outpatient setting or observation unit.
      • Common agents: Captopril (25 mg PO), Labetalol (100-200 mg PO), Clonidine (0.1-0.2 mg PO), Furosemide (20-40 mg PO).
    • Hypertensive Emergency: Severe BP elevation WITH evidence of acute, ongoing target organ damage. This is a medical emergency requiring immediate intravenous (IV) antihypertensive therapy and admission to an intensive care unit (ICU).
      • Immediate: Goals for BP reduction vary based on the clinical situation:
        • Most Emergencies (e.g., encephalopathy, acute heart failure, aortic dissection, eclampsia): Reduce Mean Arterial Pressure (MAP) by no more than 10-25% within the first hour. Then, if stable, reduce BP to 160/100-110 mmHg over the next 2-6 hours.
        • Acute Ischemic Stroke: BP lowering is generally avoided unless SBP >220 mmHg or DBP >120 mmHg (if no thrombolysis planned). If thrombolysis planned, maintain BP <185/110 mmHg.
        • Aortic Dissection: Rapidly lower SBP to <120 mmHg within minutes, if tolerated.
        • Intracranial Hemorrhage: SBP 150-220 mmHg, target SBP 140 mmHg.
      • Stabilization: Identify and manage specific organ damage (e.g., intubation for acute pulmonary edema, anti-epileptics for seizures).
      • Emergency: IV agents with rapid onset and short duration of action are preferred.
        • Nicardipine: 5-15 mg/hour IV infusion. Good for most emergencies, especially stroke.
        • Labetalol: 20 mg IV bolus, then 20-80 mg IV every 10 min, or 0.5-2 mg/min IV infusion. Good for most emergencies, safe in pregnancy, but avoid in acute heart failure or severe bradycardia.
        • Sodium Nitroprusside: 0.25-10 mcg/kg/min IV infusion. Very potent, rapid onset/offset. Used for most emergencies, but watch for cyanide toxicity with prolonged use/renal failure. Avoid in increased intracranial pressure.
        • Fenoldopam: 0.1-1.6 mcg/kg/min IV infusion. Renal vasodilator, useful in renal insufficiency.
        • Nitroglycerin: 5-100 mcg/min IV infusion. Preferred for acute coronary syndromes, acute pulmonary edema.
        • Esmolol: 500 mcg/kg loading, then 50-300 mcg/kg/min IV infusion. Preferred for aortic dissection, acute coronary syndrome.

Chronic Management

  • Pharmacological: Initiated for Stage 1 HTN with ASCVD risk ≥10% or existing ASCVD, and for all Stage 2 HTN.
    • First-Line Agents (for uncomplicated hypertension):
      1. Thiazide-type Diuretics: (e.g., Hydrochlorothiazide 12.5-25 mg/day, Chlorthalidone 12.5-25 mg/day). Effective, inexpensive, good for volume-dependent HTN.
      2. ACE Inhibitors (ACEi): (e.g., Lisinopril 10-40 mg/day, Enalapril 5-40 mg/day). Block RAAS, renoprotective, good for heart failure, diabetes, CKD.
      3. Angiotensin Receptor Blockers (ARBs): (e.g., Valsartan 80-320 mg/day, Losartan 25-100 mg/day). Similar effects to ACEi but without cough; preferred for ACEi intolerance.
      4. Calcium Channel Blockers (CCBs):
        • Dihydropyridines: (e.g., Amlodipine 2.5-10 mg/day, Nifedipine XL 30-90 mg/day). Potent vasodilators, good for isolated systolic HTN, and in Black patients.
        • Non-dihydropyridines: (e.g., Diltiazem 120-360 mg/day, Verapamil 120-480 mg/day). Also reduce heart rate; useful for concomitant angina or atrial fibrillation, but avoid in heart failure with reduced ejection fraction.
    • Second-Line/Add-on Agents (or with specific indications):
      • Beta-blockers: (e.g., Metoprolol XL 25-200 mg/day, Carvedilol 6.25-25 mg BID). Not first-line for uncomplicated HTN, but essential for post-MI, angina, heart failure (reduced EF), and certain arrhythmias.
      • Mineralocorticoid Receptor Antagonists (MRAs): (e.g., Spironolactone 25-50 mg/day, Eplerenone 25-50 mg/day). For resistant HTN, primary aldosteronism, heart failure with reduced EF. Monitor K+ and creatinine.
      • Alpha-1 Blockers: (e.g., Doxazosin 1-8 mg/day). For concomitant benign prostatic hyperplasia (BPH), but higher risk of orthostatic hypotension.
      • Direct Vasodilators: (e.g., Hydralazine, Minoxidil). Used in severe/refractory cases, often in combination with beta-blockers and diuretics.
  • Non-pharmacological: Foundation of hypertension management, often sufficient for elevated BP, and an essential adjunct to pharmacotherapy.
    • Dietary Approaches to Stop Hypertension (DASH) Diet: Emphasizes fruits, vegetables, whole grains, low-fat dairy, poultry, fish, nuts, and limits red meat, sweets, and sugar-sweetened beverages.
    • Sodium Restriction: Reduce dietary sodium to <2300 mg/day, with an ideal goal of <1500 mg/day for most adults.
    • Physical Activity: Engage in at least 150 minutes per week of moderate-intensity aerobic activity (e.g., brisk walking) or 75 minutes of vigorous-intensity activity (e.g., jogging). Add dynamic resistance exercise 2-3 times/week.
    • Weight Management: Aim for a BMI between 18.5 and 24.9 kg/m². Even a modest weight loss (5-10% of body weight) can significantly lower BP.
    • Alcohol Moderation: Limit alcohol consumption to no more than 2 standard drinks per day for men and 1 standard drink per day for women.
    • Tobacco Cessation: Counsel on smoking cessation; smoking acutely raises BP and increases cardiovascular risk.
    • Stress Management: Techniques like meditation, yoga, mindfulness can help.
  • Monitoring:
    • Regular BP measurement: Home BP monitoring is strongly encouraged.
    • Clinic visits: Frequency depends on BP control; every 3-6 months once stable.
    • Laboratory tests: Periodically check electrolytes, renal function (creatinine, eGFR), fasting glucose, and lipid panel.
    • Side effects: Monitor for medication side effects.
    • Adherence: Assess medication adherence at every visit.
    • Screening for target organ damage: Regular fundoscopic exams, ECGs, urine albumin-to-creatinine ratio (UACR).

Treatment Algorithms (ACC/AHA 2017 Recommendations)

  • Target BP for most adults: <130/80 mmHg.
  • First-Line (Initial Therapy):
    • Elevated BP (120-129/<80 mmHg): Lifestyle modifications only. Reassess in 3-6 months.
    • Hypertension Stage 1 (130-139/80-89 mmHg):
      • ASCVD risk <10% and no ASCVD: Lifestyle modifications. Reassess in 3-6 months.
      • ASCVD risk ≥10% or existing ASCVD: Lifestyle modifications + 1 antihypertensive medication. Reassess in 1 month.
    • Hypertension Stage 2 (≥140/90 mmHg): Lifestyle modifications + 2 antihypertensive medications (from different classes, e.g., ACEi/ARB + CCB or ACEi/ARB + thiazide diuretic). Reassess in 1 month.
  • Second-Line (If Target BP Not Reached):
    • If on monotherapy, add a second agent from a different first-line class.
    • If on two agents, add a third agent from a different first-line class.
    • Common effective combinations: ACEi/ARB + CCB; ACEi/ARB + thiazide diuretic; CCB + thiazide diuretic.
  • Refractory Cases (Resistant Hypertension): Defined as BP remaining above target despite adherence to optimal doses of 3 antihypertensive agents (including a diuretic) or requiring 4+ agents to achieve control.
    • Management Steps:
      1. Confirm adherence and exclude pseudo-resistance: Check proper BP measurement technique, rule out white-coat HTN (use ABPM).
      2. Rule out secondary hypertension: Thorough workup for underlying causes (renal artery stenosis, primary aldosteronism, pheochromocytoma, etc.).
      3. Optimize diuretic therapy: Ensure adequate diuresis, consider loop diuretic if eGFR <30 mL/min/1.73m².
      4. Add Mineralocorticoid Receptor Antagonist (MRA): Spironolactone (25-50 mg/day) or eplerenone is often effective as a fourth agent.
      5. Consider other add-on agents: Beta-blockers (if not already on), alpha-blockers (e.g., doxazosin), direct vasodilators (e.g., hydralazine, minoxidil).
      6. Referral to specialist: Nephrologist or hypertension specialist for further evaluation and management.

Complications

  • Common:
    • Left Ventricular Hypertrophy (LVH)
    • Chronic Kidney Disease (CKD)
    • Atherosclerosis and its manifestations: Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD).
  • Serious (often life-threatening):
    • Myocardial Infarction (MI)
    • Stroke (ischemic or hemorrhagic)
    • Heart Failure (HF) with preserved or reduced ejection fraction
    • Aortic Dissection
    • End-Stage Renal Disease (ESRD)
    • Hypertensive Encephalopathy
    • Hypertensive Retinopathy (leading to vision loss)
  • Long-term:
    • Vascular dementia
    • Aneurysms (aortic, cerebral)
    • Peripheral neuropathy

Prognosis

  • Factors Affecting Outcome:
    • Level of BP control: Consistent control significantly improves prognosis.
    • Presence and severity of target organ damage at diagnosis.
    • Presence of comorbidities (e.g., diabetes, dyslipidemia, obesity, smoking).
    • Patient adherence to lifestyle modifications and pharmacotherapy.
    • Early diagnosis and intervention.
  • Survival: Uncontrolled hypertension is a leading cause of premature death and disability worldwide. For every 20/10 mmHg increase in BP above 115/75 mmHg, the risk of death from stroke, heart disease, or other vascular disease doubles. Effective treatment significantly reduces mortality from stroke (by 35-40%), MI (by 20-25%), and heart failure (by >50%).
  • Quality of Life: Chronic complications such as stroke, heart failure, and renal failure can severely impair quality of life, leading to disability, dependence, and reduced functional capacity. Effective BP management preserves organ function and improves long-term quality of life.

Prevention

  • Primary Prevention: Preventing the initial development of hypertension.
    • Lifelong healthy lifestyle: Emphasize healthy diet (DASH principles, low sodium), regular physical activity, maintaining healthy weight, limiting alcohol, and avoiding tobacco use from childhood throughout adulthood.
    • Routine BP screening: All adults aged ≥18 years should have their BP checked at least once every 1-2 years (for normal BP) or annually (for elevated BP or risk factors).
  • Secondary Prevention: Early detection and prompt, effective management of hypertension to prevent or delay the onset of target organ damage and complications.
    • Regular monitoring: Routine clinic and home BP monitoring.
    • Adherence: Promote high adherence to prescribed antihypertensive medications and lifestyle changes.
    • Management of comorbidities: Aggressive management of associated risk factors like diabetes, dyslipidemia, and obesity.
  • Tertiary Prevention: Management of established complications to prevent further progression, improve functional outcomes, and reduce mortality.
    • Aggressive BP control: Even after complications develop, optimizing BP remains crucial.
    • Specific therapies for complications: e.g., statins for dyslipidemia, antiplatelet therapy for CAD/stroke, revascularization for PAD, dialysis/transplantation for ESRD.
    • Rehabilitation: Post-stroke physical and occupational therapy.

Special Populations

  • Pediatric:
    • Definition: BP classification uses sex, age, and height percentiles. Hypertension is defined as BP ≥95th percentile, or ≥130/80 mmHg for adolescents regardless of height.
    • Etiology: More commonly secondary hypertension (e.g., renal disease, coarctation of aorta) than essential HTN.
    • Management: Lifestyle modifications are first-line. If medication needed, ACEi/ARBs, CCBs, thiazide diuretics are commonly used.
  • Geriatric:
    • Common: Isolated systolic hypertension due to increased arterial stiffness.
    • Considerations: Higher risk of orthostatic hypotension, polypharmacy, increased sensitivity to adverse drug effects, cognitive impairment.
    • Target BP: ACC/AHA 2017 recommends <130/80 mmHg for non-frail older adults. For frail or very elderly, a less stringent target (e.g., SBP <140 mmHg) may be appropriate to avoid adverse events from overtreatment (e.g., falls, syncope).
    • Start low, go slow: Initiate therapy at lower doses and titrate slowly.
  • Pregnancy:
    • Classification:
      • Gestational Hypertension: New onset HTN after 20 weeks of gestation, without proteinuria. Resolves postpartum.
      • Preeclampsia: New onset HTN after 20 weeks with proteinuria and/or signs of end-organ dysfunction (renal, hepatic, hematologic, neurologic).
      • Chronic Hypertension: HTN present before pregnancy or diagnosed before 20 weeks of gestation.
    • Management:
      • Agents: Labetalol, Nifedipine (sustained release), and Methyldopa are preferred.
      • Contraindicated: ACE inhibitors and ARBs are absolutely contraindicated due to fetal toxicity (renal malformations, oligohydramnios, growth restriction).
      • Preeclampsia with severe features: Delivery is often the definitive treatment. Magnesium sulfate for seizure prophylaxis.
  • Comorbidities:
    • Diabetes Mellitus: Target BP <130/80 mmHg. ACEi/ARBs are preferred first-line agents due to renoprotective effects. SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated cardiovascular and renal benefits in diabetic patients, independently of BP lowering.
    • Chronic Kidney Disease (CKD): Target BP <130/80 mmHg. ACEi/ARBs are generally first-line, but closely monitor potassium and creatinine. Loop diuretics become necessary when eGFR <30 mL/min/1.73m².
    • Heart Failure (HF): ACEi/ARBs, beta-blockers, and MRAs are cornerstone therapies, benefiting both BP control and HF outcomes. CCBs (non-dihydropyridine type) are generally avoided in HF with reduced ejection fraction.
    • Coronary Artery Disease (CAD)/Post-MI: Beta-blockers and ACEi/ARBs are first-line due to their cardioprotective effects.

Clinical Pearls

  • Diagnostic:
    • "The Silent Killer": Always suspect hypertension, as it is often asymptomatic.
    • Accurate BP measurement is paramount: Improper technique is a leading cause of misdiagnosis and mismanagement. Use automated office BP, ABPM, or HBPM for diagnosis confirmation.
    • Always consider secondary hypertension in resistant HTN, new-onset HTN at extremes of age, or HTN with unusual symptoms/signs.
  • Treatment:
    • Lifestyle modifications are foundational: No medication can fully compensate for poor lifestyle choices.
    • Combination therapy is often required: Most patients will need 2 or more medications to reach target BP.
    • Treat to target: Don't just start medication; titrate and adjust until BP is at goal.
    • Adherence is key: Address barriers to adherence, simplify regimens, educate patients.
  • Pitfalls:
    • Therapeutic inertia: Failure to intensify treatment when BP is not at goal.
    • Overtreating the elderly: Leading to orthostatic hypotension, falls, and syncope. Consider a less aggressive BP target in frail older adults.
    • Ignoring white-coat or masked HTN: Use ABPM/HBPM to differentiate.
    • Not checking for secondary causes: Missing reversible forms of HTN or specific causes that require targeted treatment.
    • Not monitoring for side effects: Especially electrolytes with diuretics/RAAS inhibitors.

Recent Updates

  • Guidelines: The 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults significantly lowered BP thresholds for diagnosis and treatment compared to previous guidelines (e.g., JNC 7/8). This has led to a larger proportion of the adult population being classified as hypertensive or having elevated BP.
  • Evidence:
    • The SPRINT (Systolic Blood Pressure Intervention Trial) demonstrated significant cardiovascular benefits (lower rates of MI, stroke, heart failure, and death from cardiovascular causes) with a systolic BP target of <120 mmHg compared to <140 mmHg in high-risk non-diabetic adults. This trial influenced the lower BP targets in the 2017 ACC/AHA guidelines.
    • Emerging evidence regarding renal denervation as a potential treatment option for resistant hypertension, though its routine clinical application remains under evaluation.
    • New classes of drugs, like SGLT2 inhibitors and GLP-1 receptor agonists, initially developed for diabetes, have shown significant cardiovascular and renal benefits, including modest BP lowering, making them important considerations in diabetic patients with hypertension and ASCVD/CKD.
  • Controversies:
    • Optimal BP target in the elderly: While the 2017 ACC/AHA guideline recommends <130/80 mmHg for most older adults, some argue for a more individualized and potentially less aggressive target for very frail or institutionalized elderly patients to avoid risks like orthostatic hypotension and falls.
    • Role of non-pharmacological interventions: Despite strong evidence, implementation and adherence to intensive lifestyle modifications remain a challenge.
    • Impact of racial/ethnic disparities: Continued debate and research on addressing the higher burden and worse outcomes of hypertension in specific populations.

Key References

  • Guidelines:
    • Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018 May 15;71(19):e127-e248.
    • Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104.
  • Studies:
    • Wright JT Jr, Williamson JJ, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-16. (SPRINT Trial)
  • Reviews:
    • UpToDate: "Overview of hypertension in adults" and related topics.
    • Harrison's Principles of Internal Medicine, 21st Edition. Chapter 270: Systemic Hypertension.

Dr. Vivek's AI | For Educational Purposes Only